Luo Rongbo, Shen Beilei, Qian Bingshuo, Fan Lingjun, Zhang Junkui, Deng Xiuwen, Sun Yan, Zhang Shijun, Wang Tiecheng, Li Yuanguo, Sun Weiyang, Pang Xiaobin, Zhong Wu, Gao Yuwei
Changchun Veterinary Research Institute, State Key Laboratory of Pathogen and Biosecurity, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Chinese Academy of Agricultural Sciences, Changchun, 130122, China.
School of Pharmacy, Henan University, Kaifeng, 475004, China.
BMC Microbiol. 2025 May 15;25(1):292. doi: 10.1186/s12866-025-03847-2.
SARS-CoV-2 and influenza virus are highly contagious respiratory viruses that continuously pose major threats to human and public health. The high frequency of viral mutations led to the emergence of resistant isolates and caused virus epidemics repeatedly, emphasizing the urgent need to develop new antivirals. Taurultam is a metabolite of taurolidine. Moreover, taurolidine has been shown to have potent antiviral activities against multiple viruses and to have antiviral effects through its metabolites.
In this study, we sought to determine the antiviral activities of taurultam against SARS-CoV-2 and influenza virus in Vero-E6, Huh7, 293T-ACE2, and MDCK cell lines and mouse infection models. The results showed that taurultam exhibited potent antiviral activity against multiple SARS-CoV-2 variants, influenza A (H1N1, H3N2) virus and influenza B virus, in vitro. Moreover, in influenza A (H1N1) virus, influenza B virus and SARS-CoV-2 infection models, taurultam significantly reduced viral loads, increased survival, improved mouse body weight and lung injury. Surprisingly, taurultam treatment not only inhibited the influenza A virus and SARS-CoV-2, but also benefited for therapy of mixed infection of these two viruses in vitro, demonstrating the great antiviral potential of taurultam for the treatment of SARS-CoV-2 and influenza virus infections.
Together, our findings identify taurultam as a new candidate for the treatment of SARS-CoV-2 and influenza virus infections, especially virus-induced lung pathology.
Not applicable.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和流感病毒是具有高度传染性的呼吸道病毒，持续对人类和公共卫生构成重大威胁。病毒的高突变频率导致耐药菌株出现，并多次引发病毒流行，这凸显了开发新型抗病毒药物的迫切需求。托罗他姆是牛磺罗定的一种代谢产物。此外，牛磺罗定已被证明对多种病毒具有强大的抗病毒活性，并通过其代谢产物发挥抗病毒作用。
在本研究中，我们试图确定托罗他姆在Vero-E6、Huh7、293T-ACE2和MDCK细胞系以及小鼠感染模型中对SARS-CoV-2和流感病毒的抗病毒活性。结果表明，托罗他姆在体外对多种SARS-CoV-2变体、甲型流感（H1N1、H3N2）病毒和乙型流感病毒均表现出强大的抗病毒活性。此外，在甲型流感（H1N1）病毒、乙型流感病毒和SARS-CoV-2感染模型中，托罗他姆显著降低了病毒载量，提高了生存率，改善了小鼠体重和肺损伤。令人惊讶的是，托罗他姆治疗不仅抑制了甲型流感病毒和SARS-CoV-2，而且在体外对这两种病毒的混合感染治疗也有益处，这表明托罗他姆在治疗SARS-CoV-2和流感病毒感染方面具有巨大的抗病毒潜力。
总之，我们的研究结果确定托罗他姆是治疗SARS-CoV-2和流感病毒感染，特别是病毒诱导的肺部病变的新候选药物。
不适用。
